Preventative IP for preventative pharma healthcare

The shift towards preventative pharmaceuticals could open new, and highly valuable, markets but it must be strengthened by patent rights, says Sam Andrews, senior paralegal at Powell Gilbert.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com

More on this story

Biotech

Amgen hit with lawsuit over its proposed Opdivo biosimilar

16 September 2026 BMS is stepping up its defence of its blockbuster cancer drug Opdivo as Amgen moves closer to the biosimilar market.

Biotech

Australian biotech sues Grail over multi-cancer blood test

15 September 2026 Grail is facing a patent infringement lawsuit over its Galleri cancer detection test, as Clinical Genomics seeks to enforce its intellectual property while no longer being commercially operational.

Biotech

10x Genomics wins latest round in Parse patent dispute

3 September 2026 Turnaround for 10x after Federal Circuit setback as Delaware jury finds Qiagen-owned Parse infringed three patents covering single-cell sequencing technology.

More features

Leading European patent litigator to join Carpmaels & Ransford

CIPA Congress: Sustainability is essential for the profession and the planet

Non-profit sues Cambrex over anticancer drug manufacturing trade secrets

Amgen hit with lawsuit over its proposed Opdivo biosimilar

Beyond the primary patent: How pharma can build competitive barriers

Australian biotech sues Grail over multi-cancer blood test

K&L Gates hires six-strong team of IP and corporate lawyers from Pillsbury

Perfect Pitch: Inside the scheme that gets junior lawyers selling to clients

Preventative IP for preventative pharma healthcare

More on this story

Editor's picks

Editor's picks

More features